Agenus Represents An Undervalued Player In The Immuno-Oncology Space, Says H.C. Wainwright
In a research note issued this morning, H.C. Wainwright analyst Reni Benjamin reiterated coverage with a “Buy” rating on Agenus Inc. (AGEN), and a price target of $6.00 a share following the Phase 2, six-month booster results for AGEN’s HerpV vaccine program in genital herpes.
Benjamin comments: “We view this data positively as it serves to validate the efficacy of the HerpV program using a rigorous endpoint of viral load reduction, and in our opinion, makes the program more attractive to partners. With $64 MM in cash (pro forma), a growing pipeline of checkpoint inhibitors to enter the clinic in 2016, and the potential to secure a new partnership, we continue to believe Agenus represents an undervalued player in the immuno-oncology space”.
According to TipRanks, which measures analysts and bloggers success rate based on how their calls perform, analyst Reni Benjamin currently has a one-year average return of 4.7% and a 41% success rate. Benjamin has a -15.2% average profit recommending AGEN, and he is ranked #1464 out of 3135 analysts.